Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
Combination increases complete response rate to 24% compared to chemotherapy alone
Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting.
Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery.
The primary endpoints of the study were pathological complete response (pCR), defined as no residual viable tumour in the resected lung specimen and the sampled lymph node after surgery and event-free survival (EFS).
Maryland Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst of Karst von Oiste to Ensure a Navy Veteran with Mesothelioma in Maryland Gets the Best Compensation-It Might Exceed $1,000,000 If you are a Navy Veteran with recently diagnosed mesothelioma in Maryland or their family-we have endorsed attorney Erik Karst of the law firm to assist you with financial compensation.” Maryland Mesothelioma Victims Center
BALTIMORE , MARYLAND , USA, April 6, 2021 /EINPresswire.com/ According to the Maryland Mesothelioma Victims Center, We are one of the nation s leading advocates for people who develop mesothelioma in Maryland, and we want a person like this to receive the best possible mesothelioma compensation results-especially if they are a US Navy Veteran. If you are a Navy Veteran with recently diagnosed mesothelioma in Maryland or their family-we have endorsed attorney Erik Karst of the law firm to assist you with financial compensation. Frequently financial c
Maryland Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst of Karst von Oiste to Ensure a Navy Veteran with Mesothelioma in Maryland Gets the Best Compensation-It Might Exceed $1,000,000 einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary
RADR
® artificial intelligence ( A.I. ) platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lantern s drug candidate LP-184 in the area of brain tumors, and specifically in
Atypical
Rhabdoid
Tumors ( ATRT ), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children. As we enriched our
RADR
® A.I. platform for additional cancer indications, we began to discover common molecular pathways that drive response to our drug candidate, LP-184, across multiple additional CNS cancers, stated Panna Sharma, President and CEO of Lantern Pharma. Chief among these newly identified CNS cancers was ATRT, an ultra-rare and fast-growing cancerous tumor of the brain tha
AHN Cancer Institute Opens Genomics Facility Offering Patients Next-Generation Gene Sequencing to Guide Treatment Decisions
Share Article
Pittsburgh-based Allegheny Health Network (AHN) Cancer Institute has opened a new Clinical Genomics Laboratory, offering comprehensive, advanced, in-house genomic testing that guides doctors in selecting treatments to give cancer patients their best chance at a good outcome.
William LaFramboise, PhD, Chief Genomics Technology Officer, Allegheny Health Network, and David Bartlett, MD, Chair, AHN Cancer Institute, in AHN s new Clinical Genomics Laboratory We believe that offering on-site genomic testing offers a number of advantages to our patients, including a quicker turnaround time and better stewardship of our patients’ samples. - David L. Bartlett, MD, Chair, AHN Cancer Institute